肝细胞癌(hepatocellular carcinoma,HCC)是临床最常见的恶性肿瘤之一,男性中该病的全球发病率居第5位,女性居第7位,病死率在男性居第2位,女性居第6位[1]。而我国肝癌发病人数约占全球的55%,在肿瘤相关死亡中仅次于肺癌,居于第2位[2]。HCC多在肝纤维化、肝硬化的基础上出现,因肝脏在血脂代谢中发挥重要作用,慢性肝病患者往往出现血脂代谢异常,如胆固醇合成减少、磷脂合成障 Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in clinic. The incidence of HCC is the fifth in the world, the seventh is in the female, the second is in the male and the second is in the female 6 [1]. The incidence of liver cancer in China accounts for about 55% of the world, second only to lung cancer in cancer-related deaths, living in second place [2]. HCC mostly appear on the basis of liver fibrosis and cirrhosis. Because liver plays an important role in lipid metabolism, patients with chronic liver disease often have dyslipidemia such as reduced cholesterol synthesis,